First‐trimester exposure to tofacitinib in ulcerative colitis: A case report of a healthy newborn and literature review

Abstract

Tofacitinib is contraindicated in pregnancy. We present a patient with ulcerative colitis on tofacitinib who had an unplanned pregnancy. Tofacitinib was ceased, switched to vedolizumab, and she gave birth to a healthy newborn at term. Case reports of reassuring outcomes provide real‐world data that assists decision‐making for future patients.